JuggerStitch Device for Torn Meniscus
Trial Summary
What is the purpose of this trial?
This trial aims to confirm the safety and effectiveness of the JuggerStitch Device, which is used to repair torn knee cartilage (meniscus). It targets patients with meniscal tears to help them avoid further knee surgeries by stitching the torn parts together.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.
What data supports the effectiveness of the JuggerStitch Meniscal Repair Device treatment?
The research suggests that all-inside suture devices, like the JuggerStitch, are generally effective for meniscal repair, as they have been shown to have better outcomes compared to other methods like meniscal arrows. These devices are designed to simplify the repair process and improve the strength of the repair, which can lead to better healing.12345
Research Team
Kim Blick
Principal Investigator
Zimmer Biomet
Elliott Goff, PhD
Principal Investigator
Zimmer Biomet
Eligibility Criteria
This trial is for adults over 18 with a torn meniscus who are physically and mentally able to follow the study's procedures and attend follow-up appointments. Participants must understand and consent to the study. Those with certain types of complex meniscal tears, active infections, or pregnancy cannot join.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo meniscal repair using the JuggerStitch Device
Follow-up
Participants are monitored for safety and effectiveness after treatment
Post-market surveillance
Data collection to confirm the safety and performance of the JuggerStitch Device
Treatment Details
Interventions
- JuggerStitch Meniscal Repair Device (Device)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Zimmer Biomet
Lead Sponsor
Dr. Nitin Goyal
Zimmer Biomet
Chief Medical Officer since 2021
MD from Harvard Medical School
Ivan Tornos
Zimmer Biomet
Chief Executive Officer since 2023
MBA from the University of Miami School of Business, BBA in Finance and International Marketing and Management from the University of Georgia Terry College of Business